Latest news with #PiramalHealthcare
Economic Times
2 days ago
- Business
- Economic Times
Piramal Healthcare targets $2 bn revenue by FY30, to focus on organic expansion: Chairperson Nandini Piramal
Agencies About 69% of Piramal Pharma's revenue comes from regulated markets like the US, UK, Europe and Japan. Piramal Healthcare will focus on organic expansion as its primary growth driver for the next 4-5 years, while it looks for licensing of product acquisition deals in both complex hospital generics and consumer healthcare business, chairperson Nandini Piramal told ET in an reiterated the company's revenue target of $2 billion by FY30 despite macroeconomic volatility and sector-specific headwinds.'Our network of facilities is well-balanced and as people think about diversifying supply chains, and even think of going back to the US, I think we are well set for that. Our focus on differentiated offerings such as antibody-drug conjugate (ADCs) is seeing growth. Overall, the other businesses are also on track for that growth,' she is an area of pharmaceutical research that focuses on creating targeted cancer therapies. Talking about the current global headwinds, Piramal said near-term macro-economic uncertainty and biotech funding volatility in the US are some of the significant risk factors to watch out for in the months ahead. On Monday, the company announced its first quarter results with a net loss of Rs 82 crore in Q1 FY26 versus net loss of Rs 89 crore a year ago. Revenue from operations fell 1% year-on-year to Rs 1,934 crore. EBITDA margin for Q1 FY26 was 9% versus 11% in Q1 FY25, primarily impacted by inventory destocking. This was partly offset by improved profitability of the overseas facilities in the CDMO 69% of Piramal Pharma's revenue comes from regulated markets like the US, UK, Europe and ahead, Piramal said growth will be balanced between India, US and UK. The focus will be on broadening the customer base and getting new company is investing $90 million to expand two of its US facilities in Lexington and Lexington capability will come online in 2027, she said, and play a vital role in the company's integrated antibody-drug conjugate (ADC) development and manufacturing program.
Time of India
2 days ago
- Business
- Time of India
Piramal Healthcare targets $2 bn revenue by FY30, to focus on organic expansion: Chairperson Nandini Piramal
Piramal Healthcare will focus on organic expansion as its primary growth driver for the next 4-5 years, while it looks for licensing of product acquisition deals in both complex hospital generics and consumer healthcare business, chairperson Nandini Piramal told ET in an interaction. She reiterated the company's revenue target of $2 billion by FY30 despite macroeconomic volatility and sector-specific headwinds. Explore courses from Top Institutes in Please select course: Select a Course Category others Project Management Management Technology Product Management Finance Public Policy PGDM Degree Data Science Design Thinking Artificial Intelligence MBA Cybersecurity MCA healthcare Leadership Healthcare Digital Marketing Data Science Others Operations Management Data Analytics CXO Skills you'll gain: Duration: 16 Weeks Indian School of Business CERT - ISB Cybersecurity for Leaders Program India Starts on undefined Get Details 'Our network of facilities is well-balanced and as people think about diversifying supply chains, and even think of going back to the US, I think we are well set for that. Our focus on differentiated offerings such as antibody-drug conjugate (ADCs) is seeing growth. Overall, the other businesses are also on track for that growth,' she said. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Wakefield: This Is The Truth About "No Fuss" Cremations Golden Leaves Undo ADC is an area of pharmaceutical research that focuses on creating targeted cancer therapies. Talking about the current global headwinds, Piramal said near-term macro-economic uncertainty and biotech funding volatility in the US are some of the significant risk factors to watch out for in the months ahead. Live Events On Monday, the company announced its first quarter results with a net loss of Rs 82 crore in Q1 FY26 versus net loss of Rs 89 crore a year ago. Revenue from operations fell 1% year-on-year to Rs 1,934 crore. EBITDA margin for Q1 FY26 was 9% versus 11% in Q1 FY25, primarily impacted by inventory destocking. This was partly offset by improved profitability of the overseas facilities in the CDMO business. About 69% of Piramal Pharma's revenue comes from regulated markets like the US, UK, Europe and Japan. Going ahead, Piramal said growth will be balanced between India, US and UK. The focus will be on broadening the customer base and getting new projects. The company is investing $90 million to expand two of its US facilities in Lexington and Riverview. The Lexington capability will come online in 2027, she said, and play a vital role in the company's integrated antibody-drug conjugate (ADC) development and manufacturing program.
